NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-103-2021-0-JP-05 USE OF LENTIVECTOR TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS JP National Stage 2020-560341 Pending
NCI E-103-2021-0-SG-07 USE OF LENTIVECTOR TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS SG National Stage 11202010645V Pending
NCI E-253-2020-0-US-01 Single Domain Antibodies Targeting SARS-CoV-2 US 63/105,769 Abandoned
NCI E-094-2018-0-JP-07 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF JP National Stage 2020-559481 Issued
NCATS E-244-2014-0-AU-10 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof AU DIV 2020257163 Issued
NCATS E-193-2018-0-US-02 Improved CRISPR Therapy US National Stage 17/049,980 Pending
NIMH E-126-2018-0-US-03 NR2B LIGANDS; METHODS OF MAKING; AND USE THEREOF US National Stage 17/050,209 Abandoned
NCI E-094-2018-0-US-08 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF US National Stage 17/050,045 Pending
NIAID E-018-2018-0-IN-09 CHIMERIC VECTORS IN National Stage 202047046248 Pending
NIAID E-018-2018-0-US-12 CHIMERIC VECTORS US National Stage 17/049,916 12071632 Issued PDF
NIAID E-018-2018-0-JP-10 CHIMERIC VECTORS JP National Stage 2020-558967 Issued
NIAID E-018-2018-0-BR-05 CHIMERIC VECTORS BR National Stage BR112020021652-6 Pending
NIEHS E-125-2018-2-IL-04 USE OF EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) TARGETING AGENTS IN TREATING LUNG DISORDERS IL National Stage 278246 Pending
NCI E-185-2019-0-PCT-02 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors PCT PCT PCT/US2020/056601 Expired
NIAID E-288-2016-0-US-04 Biomarkers And Vaccine Candidates For Filarial Parasites US DIV 17/076,616 Pending
NCI E-185-2019-0-CN-05 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors CN National Stage 202080074414.2 Pending
NCI E-185-2019-0-EP-06 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors EP National Stage 20804404.0 Pending
NCI E-185-2019-0-JP-07 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors JP National Stage 2022-523456 Pending
NCI E-185-2019-0-CA-04 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors CA National Stage 3156761 Pending
NIAID E-018-2018-0-AU-04 CHIMERIC VECTORS AU National Stage 2019261570 Pending
NCI E-185-2019-0-AU-03 High Affinity Nanobodies Targeting B7-H3 (CD276) For Treating Multiple Solid Tumors AU National Stage 2020370125 Pending
NIAID E-220-2020-0-US-01 ANTIBODIES THAT NEUTRALIZE TYPE-I INTERFERON (IFN) ACTIVITY US 63/094,572 Abandoned
NIMH E-259-2016-0-US-05 RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF US DIV 17/074,832 Abandoned
NIAID E-018-2018-0-CA-06 CHIMERIC VECTORS CA National Stage 3097888 Pending
NCI E-094-2018-0-CA-04 METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF CA National Stage 3097858 Pending
NCI E-036-2021-1-US-01 Autosomal Mosaicism Detected In Blood Cell DNA Of Healthy Individuals Predicts Post-cancer Diagnosis Infection Risk US 63/093,579 Abandoned
NIAID E-004-2022-0-US-01 Star Polymer Drug Conjugates US 63/093,445 Abandoned
NHGRI E-147-2020-0-US-01 High Concentration Methylcobalamin (Me-Cbl) Or Combination Of Methyl- And Hydroxocobalamin (Me/OH-Cbl) For The Treatment Of Cobalamin C Deficiency And Related Disorders US 63/093,084 Abandoned
NIBIB E-007-2021-0-US-01 ANTIBODY SPECIFIC FOR SARS-COV-2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC
METHODS 		US 63/092,350 Abandoned
NHGRI E-175-2019-0-PCT-02 SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE BETA PCT PCT PCT/US2020/055836 Expired
NCI E-028-2015-1-SA-37 T CELL RECEPTORS SPECIFIC FOR MUTATED KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG SA DIV 520420365 Issued
NCI E-097-2018-0-EP-08 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES EP National Stage 19714007.2 Pending
NIAID E-178-2019-0-US-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS US 63/091,824 Abandoned
NCI E-040-2012-0-IL-58 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen IL DIV 278003 Pending
NCI E-097-2018-0-KR-11 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES KR National Stage 2020-7029302 Pending
NCI E-105-2012-0-EP-27 Murine Anti-NY-ESO-1 T Cell Receptors EP DIV 20201340.5 Issued
NCI E-174-2019-0-PCT-02 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA PCT PCT PCT/US2020/055077 Expired
NCI E-174-2019-0-CN-03 A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMA CN National Stage 202080071446.7 Pending
NHLBI E-219-2018-2-US-03 METHOD AND SYSTEM FOR AUTOMATICALLY GENERATING AND ANALYZING FULLY QUANTITATIVE PIXEL-WISE MYOCARDIAL BLOOD FLOW AND MYOCARDIAL PERFUSION RESERVE MAPS TO DETECT ISCHEMIC HEART DISEASE USING CARDIAC PERFUSION MAGNETIC RESONANCE IMAGING US National Stage 17/046,193 Abandoned
NCI E-100-2018-0-EP-03 3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF
TYPE II NKT CELLS AND USES THEREOF 		EP National Stage 19716658.0 Pending
NCI E-230-2012-0-KR-62 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 KR DIV 10-2020-7028713 Issued
NIAID E-185-2015-0-US-06 EXPRESSION VECTOR DELIVERY SYSTEM AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US DIV 17/064,496 Pending
NCI E-189-2020-0-US-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION US 63/086,674 Abandoned
NEI E-050-2015-0-JP-14 RP2 and RPGR Vectors for Treating X-Linked Retinitis Pigmentosa JP DIV 2020-167984 Pending
NCI E-077-2017-0-US-04 CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE US CON 17/061,464 Pending
NHLBI E-078-2019-0-US-03 HELICAL GUIDEWIRES AND RELATED SYSTEMS US ORD 17/038,095 Pending
NIAID E-131-2020-5-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/085,042 Abandoned
NCI E-105-2018-0-US-06 Biomarker Analysis Software For High-Throughput Diagnostic Multiplex Data US National Stage 17/042,765 Pending
NCI E-085-2013-0-HK-27 CD8+ T CELLS THAT ALSO EXPRESS PD-1 AND/OR TIM-3 FOR THE
TREATMENT OF CANCER 		HK EP 42020016957.1 Pending
NCI E-230-2012-0-HK-61 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 HK EP 42020016865.6 Issued